AfricaRegulatory

African Pharmaceutical Regulatory Intelligence

CONJUGATED OESTROGENS

10 registrations across 2 African markets— 7 active

Markets with CONJUGATED OESTROGENS

Recent registrations

Brand / ProductMarketHolderStatusExpires
PREMARIN
TABLET, COATED; ORAL
🇿🇼ZimbabwePFIZER LABORATORIES (PTY) LTD, S.AactiveDec 2027
PREMARIN
TABLET, COATED; ORAL
🇿🇼ZimbabwePFIZER LABORATORIES (PTY) LTD, S.AactiveDec 2027
PREMARIN
CREAMS
🇿🇼ZimbabwePFIZER LABORATORIES (PTY) LTD, S.AactiveDec 2027
PREMARIN
TABLET, COATED; ORAL
🇿🇼ZimbabwePFIZER LABORATORIES (PTY) LTD, S.AactiveDec 2027
PREMELLE 5🇿🇦South AfricaPfizer Laboratories (Pty) LtdsuspendedJul 2025
PREMELLE LD-0,3/1,5🇿🇦South AfricaPfizer Laboratories (Pty) LtdsuspendedJul 2025
PREMELLE 2,5🇿🇦South AfricaPfizer Laboratories (Pty) LtdsuspendedJun 2025
PREMARIN 0,625🇿🇦South AfricaPfizer Laboratories (Pty) LtdactiveJan 1900
PREMARIN 0,3🇿🇦South AfricaPfizer Laboratories (Pty) LtdactiveJan 1900
PREMARIN 1,25🇿🇦South AfricaPfizer Laboratories (Pty) LtdactiveJan 1900

CONJUGATED OESTROGENS in Africa — Regulatory Overview

CONJUGATED OESTROGENS is registered across 2 African markets with 10 total product registrations on file. Data is sourced directly from official national drug regulatory authorities including South Africa, Zimbabwe. AfricaRegulatory refreshes this data daily from official government sources.

Of the 10 registrations, 7 (70%) are currently active. Regulatory affairs teams use AfricaRegulatory to track registration expiry dates, identify market incumbents, and monitor approval status across African markets without manual monitoring of each national regulator.